Dear families, dear colleagues,
We welcome you on our website. Cancer predisposition syndromes (CPS) are genetic conditions associated with an increased cancer risk. CPS are especially relevant for children and adolescents with cancer. We are a team of scientists and pediatric oncologists and it is our aim to advance CPS research, together with affected individuals and their families other scientists and health professionals: through Facts, Investigation, and Therapy.
Here on our website, we concisely review CPS relevant for children, including the medical background and therapeutic measures, for families affected by a CPS and for health professionals. You will also find links to support groups and relevant articles.
We would like to learn more about the cancer risks in individuals affected by a CPS and about the biology underlying cancer development in these patients. We also would like to collect data on the benefit of cancer surveillance. Therefore, we have launched a CPS registry.
We are just beginning to understand the urgent need of better cancer therapies for individuals with CPS. Therefore, it is important to further advance cancer therapies for CPS patients. We are promoting this process though our own research and by collaborating with the various childhood cancer study groups of the Society of Pediatric Oncology and Hematology.
We are just beginning to understand the important role of CPS, especially in children affected by cancer. We would like to accelerate this process. In case you have questions related to CPS or if you wish to support our work, we are looking forward to receiving your message!
Christian P. Kratz, MD Stefan M. Pfister, MD
Cancer Predisposition Syndrome Registry
Genetic cancer predisposition is the most important known cause of childhood cancer. By launching the CPS-Registry, we would like to
define the cancer risks associated with CPS
investigate the mechanisms of cancer development in CPS patients
examine, if cancer surveillance improves the health of affected individuals.
Treating physicians, please support our work by enrolling patients into our registry. Please note, during the initial phase of our registry, only patients with Li-Fraumeni syndrome can be enrolled.
About us – our teams in Hannover and Heidelberg
Hannover
| +49 511 532-6712 | |
| +49 511 532-9120 | |
| Kratz.Christian@mh-hannover.de | |
| Department of Paediatric Haematology and Oncology at Hannover Medical School (MHH) |
Heidelberg
| +49 6221 42-4617 | |
| +49 6221 42-4639 | |
| s.pfister@kitz-heidelberg.de | |
| “Hopp Children’s Cancer Center at NCT Heidelberg (KiTZ)” |
News about our scientific work
Start of the “Liquid Biopsy” project
Based on the Cancer Predisposition Syndrome Registry, the Liquid Biopsy project is now starting. The aim is to detect small DNA fragments of tumor cells in the blood. In the future, this will enable the early and least invasive detection of the development and process of malignant diseases.
Integration of FAR01 in LFS-CPS-R01
The Fanconi Anaemia Registry has been affiliated to the Cancer Predisposition Syndrome Registry since January 2020. This has significantly simplified the administrative structures. However, this does not change anything for the registered patients. A click on the picture above will take you to further information about the affiliation.
LFS Family Meeting 2019
In September, the second German LFS family meeting took place in Hannover with a very positive response! 50 participants used the meeting for mutual exchange and discussions with experts. In addition, various specialist lectures were offered and many questions from those affected were discussed and clarified in a warm atmosphere.
Genetic Cancer Predisposition Working Group of the Society of Pediatric Oncology and Hematolgy (GPOH)
The Genetic Cancer Predisposition Working Group of the Society of Pediatric Oncology and Hematolgy is an expert committee, that focusses on CPS in children. The group has the following aims:
Investigating the role of germline genetic changes as the cause of childhood cancer
Improving the cancer surveillance, treatment and care for children with CPS
Investigating the biologic basis of cancer in children with CPS
We meet on a regular basis to discuss collaborative projects in order to move the field forward. We also discuss complex cases and provide second opinions. Information on our working groups can also be found on the webpage of our society.
Members
Christian Kratz, Stefan Pfister
Stefan S. Bielack, Arndt Borkhardt, Ines B. Brecht, Birgit Burkhardt, Gabriele Calaminus, Klaus-Michael Debatin, Hedwig Deubzer, Uta Dirksen, Beate Dörgeloh, Martin Ebinger, Cornelia Eckert, Angelika Eggert, Miriam Erlacher, Jörg Faber, Gudrun Fleischhack, Michael C. Frühwald, Nicolas Gerber, Astrid Gnekow, Norbert Graf, Julia Hauer, Barbara Hero, Simone Hettmer, Katja von Hoff, Martin Horstmann, Björn-Ole Juhnke, Ariana Kamawal, Kornelius Kerl, Thomas Klingebiel, Udo Kontny, Uwe Kordes, Dieter Körholz, Ewa Koscielniak, Christof M. Kramm, Michaela Kuhlen, Andreas E. Kulozik, Andrea Meinhardt, Markus Metzler, Lüder H. Meyer, Olga Moser, Michaela Nathrath, Charlotte M. Niemeyer, Kristian W. Pajtler, Claudia Paret, Alexandra Russo, Stefan Rutkowski, Irene Schmid, Dominik Schneider, Reinhard Schneppenheim, Martin Schrappe, Peter Schütte, Thorsten Simon, Monika Sparber-Sauer, Arend von Stackelberg, Martin Stanulla, Brigitte Strahm, Petra Temming, Andre O. von Bueren, Peter Vorwerk, Olaf Witt, Marcin Wlodarski, Willy Wössmann, Stefanie Zimmermann
Thomas Illig, Dietmar R. Lohmann, Tim Ripperger, Brigitte Schlegelberger, Olaf Rieß, Christopher Schroeder, Doris Steinemann, Martin Zenker, Gudrun Goehring, Juliane Hoyer, Kathrin Thomay, Susanne Morlot, Lisa Pahl, Kerstin Grund, Nicola Dikow
Rita Schmutzler, Sarah Schott
Peter Kaatsch, Claudia Spix
Rainer Nustede, Dietrich von Schweinitz, Roland Kappler, Kristina Becker
Frank Wacker
Ulrich Schüller
Recent publications about CPS
This article, published in the Journal of Clinical Oncology, reports on a novel gene mutation, GPR161, which predisposes to medulloblastomas. It has been described that this mutation is associated with an increased risk of MB SHH tumors in infants. A click on the publication title leads you directly to the article. |
In this letter-to-the-editor article, published in the journal “Haematologica”, TP53, ETV6 and RUNX1 genes were analyzed to characterize their potential impact on second neoplasia development after ALL therapy in childhood. A click on the publication title takes you directly to the article. |
In this article, published in the Journal of Medical Genetics, guidelines for the diagnosis of constitutional mismatch repair-deficiency syndrome (CMMD) as differential diagnosis of neurofibromatosis type 1 were published. A click on the publication title takes you directly to the article. |
This article, published in the “Journal of Clinical Oncology”, reports about the cancer risk of DICER1 mutations and lists recommendations for genetic counseling. A click on the publication title takes you directly to the article. |